간경변증 여부와 관계 없이 모든 유전자형의 만성 C형간염 환자에서 효과가 있는 직접 작용 항바이러스제 = Direct Acting Antivirals Which Is Effective in Pan-genotypic Chronic Hepatitis C Patients with or without Liver Cirrhosis

참고문헌 (Reference)

1 Lawitz E, "Sofosbuvir for previously untreated chronic hepatitis C infection" 368 : 1878-1887, 2013

2 Jacobson IM, "Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options" 368 : 1867-1877, 2013

3 Foster GR, "Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection" 373 : 2608-2617, 2015

4 Feld JJ, "Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection" 373 : 2599-2607, 2015

5 Zeuzem S, "Sofosbuvir and ribavirin in HCV genotypes 2 and 3" 370 : 1993-2001, 2014

6 Alqahtani SA, "Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: analysis of phase III ION trials" 62 : 25-30, 2015

7 Afdhal N, "Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection" 370 : 1889-1898, 2014

8 Afdhal N, "Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection" 370 : 1483-1493, 2014

9 Gane EJ, "Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection" 149 : 1454-1461, 2015

10 Edward J. Gane, "Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 Trial" Elsevier BV 151 (151): 902-909, 2016

11 Eric Lawitz, "Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial" Elsevier BV 151 (151): 893-901.e1, 2016

12 Kumada H, "Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection" 59 : 2083-2091, 2014

13 Manns M, "All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study" 384 : 1597-1605, 2014